Team Hewins LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

Team Hewins LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,090 shares of the company’s stock, valued at approximately $413,000.

Several other institutional investors also recently bought and sold shares of ZTS. Hohimer Wealth Management LLC increased its stake in shares of Zoetis by 1.2% during the fourth quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after buying an additional 52 shares during the period. Forum Financial Management LP raised its holdings in shares of Zoetis by 0.8% in the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock valued at $1,458,000 after purchasing an additional 56 shares in the last quarter. Prossimo Advisors LLC lifted its position in shares of Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares during the period. River Street Advisors LLC boosted its stake in shares of Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock valued at $347,000 after purchasing an additional 58 shares in the last quarter. Finally, Perigon Wealth Management LLC increased its holdings in Zoetis by 0.3% during the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock valued at $4,654,000 after buying an additional 59 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS traded down $0.83 during trading on Friday, reaching $170.07. 1,893,824 shares of the company’s stock were exchanged, compared to its average volume of 2,946,235. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company’s fifty day simple moving average is $164.11 and its 200-day simple moving average is $179.62. The stock has a market capitalization of $77.60 billion, a P/E ratio of 32.77, a price-to-earnings-growth ratio of 2.65 and a beta of 0.86.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period last year, the company earned $1.31 earnings per share. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. As a group, research analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is presently 33.33%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ZTS shares. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group reduced their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Barclays lowered their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. HSBC reduced their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $211.75.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.